Breaking News Instant updates and real-time market news.

ANGO

AngioDynamics

$16.90

0.13 (0.78%)

, INSM

Insmed

$14.43

-0.79 (-5.19%)

07:42
11/29/16
11/29
07:42
11/29/16
07:42

Piper Jaffray to hold a conference

28th Annual Piper Jaffray Healthcare Conference is being held in New York on November 29-30 with webcasted company presentations to begin on November 29 at 7:30 am; not all company presentations may be webcasted. Webcast Link

ANGO

AngioDynamics

$16.90

0.13 (0.78%)

INSM

Insmed

$14.43

-0.79 (-5.19%)

NXTM

NxStage Medical

$25.85

-0.18 (-0.69%)

TDOC

Teladoc

$17.95

-0.2 (-1.10%)

ANIK

Anika Therapeutics

$46.10

-0.53 (-1.14%)

RXDX

Ignyta

$6.60

-0.15 (-2.22%)

WMGI

Wright Medical

$23.34

-0.46 (-1.93%)

AXGN

AxoGen

$8.45

-0.35 (-3.98%)

IRIX

IRIDEX

$15.33

-0.33 (-2.11%)

HQY

HealthEquity

$43.40

-0.12 (-0.28%)

INCY

Incyte

$105.17

-2.56 (-2.38%)

IPXL

Impax

VNDA

Vanda

$17.10

-0.2 (-1.16%)

  • 29

    Nov

  • 29

    Nov

  • 30

    Nov

  • 01

    Dec

  • 03

    Dec

  • 04

    Dec

  • 06

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

ANGO AngioDynamics
$16.90

0.13 (0.78%)

04/05/16
ADAM
04/05/16
DOWNGRADE
ADAM
Hold
AngioDynamics downgraded to Hold from Buy at Canaccord
04/08/16
PIPR
04/08/16
INITIATION
Target $12
PIPR
Neutral
AngioDynamics assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Brooks West assumed coverage of AngioDynamics with a Neutral rating and $12 price target. The company's investment is clouded in the near-term given the recent management changes, West tells investors in a research note following AngioDynamics' Q3 results.
11/03/16
CANT
11/03/16
INITIATION
Target $19
CANT
Buy
AngioDynamics initiated with a Buy at Cantor
Cantor Fitzgerald analyst Bryan Brokmeier started AngioDynamics with a Buy rating and $19 price target.
11/04/16
11/04/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: Yum China (YUMC) initiated with a Market Perform at Bernstein. 2. PTC (PTC) initiated with a Buy at Goldman. 3. ALLETE (ALE) initiated with a Neutral at Macquarie. 4. Array BioPharma (ARRY) initiated with an Outperform at Cowen. 5. AngioDynamics (ANGO) initiated with a Buy at Cantor. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
INSM Insmed
$14.43

-0.79 (-5.19%)

03/15/16
STFL
03/15/16
INITIATION
Target $23
STFL
Buy
Insmed initiated with a Buy at Stifel
Target $23.
06/09/16
LEER
06/09/16
NO CHANGE
Target $21
LEER
Outperform
Insmed withdrawal in Europe a minor setback, says Leerink
Leerink analyst Joseph Schwartz says Insmed decided to withdraw its Marketing Authorization Application from the European Medicines Agency for its Arikayce in treating patients with nontuberculous mycobacterium infections. The analyst sees this setback as minor as Phase 3 CONVERT study continues to enroll patients allowing the company to return with "better, more convincing" clinical data at a later date. Schwartz reiterates an Outperform rating on the stock but lowered his price target on the shares to $21 from $23.
12/18/15
SBSH
12/18/15
DOWNGRADE
Target $7
SBSH
Neutral
Synergy Pharmaceuticals downgraded to Neutral from Buy at Citi
Citi analyst Liav Abraham downgraded Synergy Pharmaceuticals (SGYP) to Neutral saying the commercial potential of plecanatide will be "significantly lower" than that of Linzess. He also views the probability of a takeout of the company as less likely. The analyst cut his price target for the shares to $7 from $12. Abraham calls Synergy and Insmed (INSM) his least favored small-cap Specialty Pharma names for 2016.
06/09/16
PIPR
06/09/16
NO CHANGE
Target $24
PIPR
Overweight
Insmed withdrawal in Europe does little to change outlook, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Insmed's decision to withdraw its Marketing Authorization Application from the European Medicines Agency for Arikayce for the treatment of nontuberculous mycobacteria lung disease does little to change the company's outlook. Like the FDA, the European regulators want to see the results of the full Phase 3 Convert study, which will report in 2017, Schimmer tells investors in a research note. Success in the Phase 3 trial likely would have been needed to stay on the market anyways, the analyst contends. He keeps an Overweight rating on Insmed with a $24 price target.
NXTM NxStage Medical
$25.85

-0.18 (-0.69%)

10/31/16
PIPR
10/31/16
NO CHANGE
Target $27
PIPR
Overweight
CMS payment system decision positive for NxStage, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien views Friday's Centers for Medicare and Medicaid Services final prospective payment system decision for end-stage renal disease as a net positive for NxStage Medical in a few areas. First, CMS "meaningfully increased" the training add-on payment for home dialysis by 91%, O'Brien tells investors in a research note. Second, the maximum number of training days for Home Hemodialysis is now 25, the analyst points out. He believes the two changes will provide enough incentive to centers to drive more adoption of Home Hemodialysis to treat end-stage renal disease. The analyst keeps an Overweight rating on the shares with a $27 price target.
11/04/16
PIPR
11/04/16
NO CHANGE
Target $27
PIPR
Overweight
Piper sees 'lots to like' in NxStage Medical quarter
Piper Jaffray analyst Matt O'Brien continues to recommend purchase of NxStage Medical shares following the company's Q3 results. He sees "lots to like" in the quarter and for the 2017 HHD business outlook. The analyst believes NxStage is executing well and keeps an Overweight rating on the shares with a $27 price target.
11/18/16
PIPR
11/18/16
NO CHANGE
PIPR
Overweight
Piper says NxStage Medical is still a name to own
After hosting investor meetings with management, Piper Jaffray analyst Matt O'Brien says NxStage Medical is still a name to own despite the stock's 20% rally year-to-date. The core HHD business is seeing "significant momentum," O'Brien tells investors in a research note. The analyst believes new capitation programs for dialysis patients could accelerate adoption of HHD. He keeps an Overweight rating on NxStage Medical with a $27 price target.
11/01/16
EAMC
11/01/16
INITIATION
Target $14
EAMC
Sell
NxStage Medical initiated with a Sell at Empire
Empire analyst Dr. Cathy Reese initiated NxStage with a Sell and a $14 price target. The analyst said increased competition from novel PD and home hemodialysis systems will transform the market and make it difficult for NxStage to reach its goal of $700M in revenues by 2020.
TDOC Teladoc
$17.95

-0.2 (-1.10%)

10/03/16
COWN
10/03/16
NO CHANGE
Target $23
COWN
Outperform
Teladoc fundamentals continue to improve, says Cowen
Cowen analyst Charles Rhyee was positive on Teladoc following investor meetings. He believes fundamentals continue to improve and that current levels represent an attractive entry point despite its shelf offering filed last week indicating a potential secondary offering. Rhyee reiterated his Outperform rating and $23 price target on Teladoc shares.
11/16/16
CHDN
11/16/16
INITIATION
Target $24
CHDN
Buy
Teladoc initiated with a Buy at Chardan
Chardan analyst Steven Wardell initiated Teladoc with a Buy and a $24 price target.
11/28/16
CHLM
11/28/16
INITIATION
Target $24
CHLM
Buy
Teladoc initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Matt Hewitt initiated Teladoc with a Buy and a $24 price target saying shares are compelling at current levels and poised to take off. The analyst said Teladoc has made significant investments building out the company's extensive 24/7 nationwide network of state licensed physicians, sales/marketing costs undertaken to establish telehealth as a viable and less costly alternative to traditional care.
07/11/16
PIPR
07/11/16
NO CHANGE
Target $22
PIPR
Overweight
Teladoc revenue guidance has upside potential, says Piper Jaffray
Piper Jaffray analyst Sean Wieland views Teladoc's revenue guidance as conservative and thinks any upward revision could be a positive catalyst. The company's new broker access is going unnoticed, Wieland tells investors in a research note. He raised his price target for the shares to $22 from $20 and keeps an Overweight rating on the shares.
ANIK Anika Therapeutics
$46.10

-0.53 (-1.14%)

12/10/15
JMPS
12/10/15
NO CHANGE
JMPS
Regulatory delay for competitor positive for Carbylan, says JMP Securities
After the FDA determined that Carbylan's (CBYL) competitor, Anika (ANIK), would have to resubmit its new drug application, JMP Securities views the news as positive for Carbylan. The firm keeps a $13 price target and Outperform rating on Carbylan.
04/27/16
NORL
04/27/16
DOWNGRADE
NORL
Market Perform
Anika Therapeutics downgraded to Market Perform from Outperform at Northland
RXDX Ignyta
$6.60

-0.15 (-2.22%)

05/11/16
PIPR
05/11/16
NO CHANGE
Target $32
PIPR
Overweight
Piper still surprised by Ignyta's 'modest valuation'
Piper Jaffray analyst Joshua Schimmer says he remains surprised by Ignyta's "modest valuation" given the company's "multiple attractive assets." Ignyta reported Q1 results last night provided some useful updates on entrectinib and taladegib, Schimmer tells investors in a research note. He keeps an Overweight rating on the shares with a $32 price target.
04/18/16
LEER
04/18/16
NO CHANGE
LEER
Outperform
Ignyta entrectinib continues to show 'encouraging' efficacy, says Leerink
Leerink analyst Paul Matteis says Ignyta's (RXDX) entrectinib continues to show "encouraging" efficacy and safety in an expanding sample of treated patients, following updated Phase 1 data presented by the company. The analyst says entrectinib shows "strong efficacy" in ROS1 with an 86% response rate, an 85% response rate in non-small cell lung cancer and multiple responses past 18 months. Loxo Oncology's (LOXO) LOXO-101, a competing inhibitor, also showed "nice efficacy data" with a comparable response rate, Matteis tells investors in a research note. The analyst reiterates an Outperform rating on Ignyta's shares.
06/23/16
JPMS
06/23/16
INITIATION
Target $15
JPMS
Overweight
Ignyta initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Ignyta with an Overweight rating and $15 price target, saying the company's lead program entrectinib is underappreciated from both a clinical and commercial perspective. Rama also views taladegib and RXDX-105 as interesting assets and potential long-term value drivers, though they are not currently included in the valuation model used to arrive at the $15 target.
04/18/16
PIPR
04/18/16
NO CHANGE
Target $32
PIPR
Overweight
Ignyta remains a top pick at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Ignyta (RXDX) remains a top pick after the company over the weekend reported additional data from the ongoing entrectinib Phase 1 ALKA and STARTRK studies. The data continue to highlight the clinical activity in solid tumors as well as a generally tolerable profile, Schimmer tells investors in a research note. Loxo Oncology (LOXO) also reported Phase 1 data for an NTRK inhibitor, and the two drugs "appear fairly similar," the analyst contends. Schimmer believes this should help drive positive sentiment for Ignyta since there was investor concern that the Loxo data would appear superior. He keeps an Overweight rating on Ignyta with a $32 price target.
WMGI Wright Medical
$23.34

-0.46 (-1.93%)

11/03/16
WBLR
11/03/16
NO CHANGE
WBLR
Outperform
Wright Medical settlement removes litigation overhang, says William Blair
William Blair analyst Kaila Krum noted that Wright Medical announced that it has reached a Master Settlement Agreement in its metal-on-metal hip litigation and also entered an agreement with three of its insurance carriers, which she believes address a "significant proportion" of the potential impact and removes a "meaningful overhang" on the stock. Krum, who has been impressed by the company's performance in recent quarters believes the company will "prove quite compelling" as a takeout target for a larger player in the long-term, keeps an Outperform rating on Wright shares.
07/13/16
JPMS
07/13/16
UPGRADE
Target $26
JPMS
Overweight
Wright Medical upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Andrew Hanover upgraded Wright Medical to Overweight after assuming coverage of the name. Wright over the past year has transformed into the only publicly traded orthopedics company with a revenue base of over $500M and a projected top-line growth rate north of 10%, Hanover tells investors in a research note. The analyst sees strong underlying fundamentals and upped his price target for the shares to $26 from $21. Piper Jaffray this morning also upgraded Wright Medical.
07/13/16
07/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pandora (P) upgraded to Overweight from Neutral at Piper Jaffray with analyst Stan Meyers saying the company is nearing an inflection point and that "meaningful upside" lies ahead. 2. Murphy Oil (MUR) upgraded to Overweight from Equal Weight at Barclays with analyst Paul Cheng saying the global oil market is currently in the "midst of a continued upward trajectory" in which Brent could average $85 by the fourth quarter of 2017 and $80-$90 between 2018 and 2021. 3. NuVasive (NUVA) upgraded to Overweight from Neutral at JPMorgan with analyst Andrew Hanover saying the company's first quarter outperformance "was not a fluke." 4. PSEG (PEG) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Stephen Byrd saying he expects stronger post-2017 earnings power based on the company's significant pipeline of regulated investment opportunities and the upcoming rate case to be filed in 2017. 5. Wright Medical (WMGI) upgraded to Overweight from Neutral at JPMorgan with analyst Andrew Hanover saying Wright over the past year has transformed into the only publicly traded orthopedics company with a revenue base of over $500M and a projected top-line growth rate north of 10%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/16
PIPR
08/16/16
NO CHANGE
Target $27
PIPR
Overweight
Piper views Augment July sales drop as 'glass half full'
Piper Jaffray analyst Matt O'Brien says recently posted July sales for Wright Medical's Augment of $1.4M are a decline when compared to June and May. O'Brien admits the number appears negative, but says he's viewing the data "more glass half full." The first month in a quarter is usually the lowest and July is one of the peak summer months for seasonality, the analyst tells investors in a research note. O'Brien keeps an Overweight rating on Wright with a $27 price target.
AXGN AxoGen
$8.45

-0.35 (-3.98%)

08/04/16
JMPS
08/04/16
NO CHANGE
JMPS
AxoGen price target raised to $13 from $8 at JMP Securities
JMP Securities analyst David Turkaly raised his price target on AxoGen after the company reported stronger than expected results. The analyst continues to believe that the company's product "can become a new standard of care in nerve repair." He keeps an Outperform rating on the shares.
08/04/16
JMPS
08/04/16
NO CHANGE
JMPS
AxoGen price target raised to $13 from $8 at JMP Securities
JMP Securities analyst David Turkaly raised his price target on AxoGen after the company reported stronger than expected results. The analyst continues to believe that the company's product "can become a new standard of care in nerve repair." He keeps an Outperform rating on the shares.
11/03/16
LSCM
11/03/16
DOWNGRADE
Target $9
LSCM
Hold
AxoGen downgraded to Hold from Buy at Lake Street
Lake Street analyst Bruce Jackson downgraded AxoGen to Hold from Buy citing valuation. The analyst keeps a $9 price target on the shares.
11/22/16
LSCM
11/22/16
UPGRADE
Target $11
LSCM
Buy
AxoGen upgraded to Buy from Hold at Lake Street
Lake Street analyst Bruce Jackson upgraded AxoGen to Buy saying the "story is revived' following yesterday's analyst meeting. The company unveiled a new product for adhesion prevention called Avive along with two other pipeline development programs in breast reconstruction and lower limb iatrogenic nerve injury, Jackson tells investors in a research note. The analyst raised his price target for the shares to $11 from $9.
IRIX IRIDEX
$15.33

-0.33 (-2.11%)

HQY HealthEquity
$43.40

-0.12 (-0.28%)

09/07/16
RHCO
09/07/16
NO CHANGE
RHCO
HealthEquity market share gains appear to be continuing, says SunTrust
After HealthEquity reported stronger than expected Q2 results, SunTrust analyst Sandy Draper says that the company's "secular trends remain positive." The analyst says that the company's growth is outpacing its sector, indicating that it's gaining market share. He keeps a Buy rating on the stock.
03/28/16
BRRR
03/28/16
NO CHANGE
Target $30
BRRR
Outperform
HealthEquity price target raised to $30 from $24 at Barrington
Barrington analyst Alexander Paris Jr. raised his price target on HealthEquity to $30 from $24 after the company recently reported better than expected Q4 results and gave better than expected guidance, saying that he believes the stock deserves a premium multiple given the company's market-leading position and the visibility of its revenues. The analyst keeps an Outperform rating on the stock.
10/28/16
JPMS
10/28/16
INITIATION
Target $43
JPMS
Overweight
HealthEquity assumed with an Overweight at JPMorgan
JPMorgan analyst Stephanie Davis assumed coverage of HealthEquity with an Overweight rating and $43 price target after taking over lead coverage from Lisa Gill.
06/08/16
RHCO
06/08/16
NO CHANGE
RHCO
HealthEquity price target raised to $40 from $34 at SunTrust
SunTrust believes that HealthEquity reported "solid" Q1 results,and the firm continues to expect the company to benefit from strong account growth going forward. It keeps a Buy rating on the shares.
INCY Incyte
$105.17

-2.56 (-2.38%)

11/17/16
LEER
11/17/16
NO CHANGE
Target $115
LEER
Outperform
Incyte price target raised to $115 from $101 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $115 from $101 after Gilead (GILD) reported disappointing top-line results from two Phase III studies evaluating momelotinib, its JAK1/2 inhibitor for patients with myelofibrosis. The analyst believes that the removal of this uncertainty on the revenue outlook of Incyte's key commercial product, combined with increasing prospects of a repatriation holiday should make the company more attractive as an acquisition target. He reiterates an Outperform rating on Incyte's shares.
11/17/16
BMOC
11/17/16
NO CHANGE
BMOC
Incyte drug won't have 'meaningful competition,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says that "mixed data" on Gilead's (GILD) momelotinib in myelofibrosis eliminates any "meaningful competition" faced by Incyte's (INCY) Jakafi in the disease. The analyst raised his price target on Incyte to $126 from $121 and keeps an Outperform rating on the shares.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.
11/18/16
RHCO
11/18/16
NO CHANGE
RHCO
Incyte has several positive catalysts, says SunTrust
SunTrust analyst PEter Lawson says he expects Incyte's baricitinib, which he calls a key profitability driver for the company, to be approved by the FDA next quarter. He also expects the company to benefit from positive data on its epacadostat and IOs in solid tumor settings. The analyst keeps a Buy rating on the shares.
IPXL Impax

11/14/16
WBTH
11/14/16
DOWNGRADE
WBTH
Hold
Impax downgraded earlier to Hold from Buy at WallachBeth
11/11/16
UBSW
11/11/16
NO CHANGE
Target $12
UBSW
Sell
Impax price target lowered to $12 from $21 Impax at UBS
UBS analyst Marc Goodman lowered his price target on Impax (IPXL) to $12 from $21 as he believes the company's fundamentals continue to deteriorate. The analyst believes the company overpaid for Teva's (TEVA) products and due to price concessions is now estimating revenues to be about 50% of his previous estimate. Goodman reiterated his Sell rating on Impax shares.
11/07/16
11/07/16
DOWNGRADE
Target $19

Underperform
Impax downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill downgraded Impax to Underperform from Neutral and lowered its price target to $19 from $29. Analyst Sumant Kulkarni believes Impax could be at risk of achieving its 2016 earnings outlook of $1.57-$1.70 given a lot needs to go right to execute against its outlook including significant growth in generics and recently acquired products from Teva/Allergan. He believes investors could "shoot first, ask later" when it reports on Wednesday given sentiment in the Specialty Pharma environment and a strong 2016 outlook is crucial.
11/10/16
LEER
11/10/16
NO CHANGE
Target $15
LEER
Market Perform
Impax price target lowered to $15 from $24 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Impax to $15 from $24 after Q3 results for the company were relatively in line, but management dramatically reduced sales and EPS guidance reflecting continued competitive pressures in the U.S. generic space. The analyst reiterates a Market Perform rating on the shares.
VNDA Vanda
$17.10

-0.2 (-1.16%)

10/06/16
JEFF
10/06/16
INITIATION
Target $23
JEFF
Buy
Vanda assumed with a Buy at Jefferies
Jefferies analyst Matthew Andrews assumed coverage of Vanda Pharmaceuticals with a Buy rating and raised his price target for the shares to $23 from $15. The analyst sees further upside in the stock as U.S. Fanapt sales continue improving and Hetlioz sees "steady" growth.
11/09/16
11/09/16
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. ConAgra (CAG) resumed with an Overweight at JPMorgan. 2. Lydall (LDL) initiated with a Buy at Roth Capital. 3. Points International (PCOM) initiated with a Buy at Citi. 4. Vanda (VNDA) initiated with a Buy at Aegis. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/16
AGIS
11/09/16
INITIATION
Target $24
AGIS
Buy
Vanda initiated with a Buy at Aegis
Aegis analyst Difei Yang initiated Vanda with a Buy and a $24 price target.
11/02/16
11/02/16
NO CHANGE

Vanda still sees FY16 revenue $143M-$153M, consensus $147.51M

TODAY'S FREE FLY STORIES

XOM

Exxon Mobil

$87.04

-0.2 (-0.23%)

21:12
12/04/16
12/04
21:12
12/04/16
21:12
Periodicals
Trump widens Secretary of State search, will interview Exxon Mobil CEO, WSJ says »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

21:08
12/04/16
12/04
21:08
12/04/16
21:08
Periodicals
Novartis CEO downplays possibility of Actelion bid, Reuters says »

Asked whether Novartis…

NVS

Novartis

$68.17

0.42 (0.62%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCRFY

Panasonic

$10.58

0.19 (1.83%)

21:05
12/04/16
12/04
21:05
12/04/16
21:05
Periodicals
Panasonic eyes European headlight maker ZKW, Nikkei says »

Panasonic plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$109.90

0.41 (0.37%)

21:03
12/04/16
12/04
21:03
12/04/16
21:03
Hot Stocks
Apple comments on U.S. autonomous cars policy, says 'excited' about potential »

The U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

20:46
12/04/16
12/04
20:46
12/04/16
20:46
Hot Stocks
Army says will not grant easement for Dakota Access Pipeline »

The Department of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

20:25
12/04/16
12/04
20:25
12/04/16
20:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

AGIO

Agios Pharmaceuticals

$56.97

-1.09 (-1.88%)

20:11
12/04/16
12/04
20:11
12/04/16
20:11
Hot Stocks
Agios Pharmaceuticals reports data on AG-348, AG-519 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:59
12/04/16
12/04
19:59
12/04/16
19:59
Hot Stocks
Karyopharm reports updated Phase 2b STORM data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ABBV

AbbVie

$59.43

0.27 (0.46%)

19:56
12/04/16
12/04
19:56
12/04/16
19:56
Hot Stocks
AbbVie reports data from two IMBRUVICA combination studies »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ABBV

AbbVie

$59.43

0.27 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

BPMC

Blueprint Medicines

$27.01

-0.99 (-3.54%)

19:50
12/04/16
12/04
19:50
12/04/16
19:50
Hot Stocks
Blueprint Medicines reports Phase 1 BLU-285 data »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

19:45
12/04/16
12/04
19:45
12/04/16
19:45
Hot Stocks
Incyte reports pooled analysis of five-year Jakafi data »

Incyte announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

GPRO

GoPro

$9.70

-0.12 (-1.22%)

19:42
12/04/16
12/04
19:42
12/04/16
19:42
Hot Stocks
GoPro releases $299 'Karma Grip' camera stabilizer »

GoPro announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:37
12/04/16
12/04
19:37
12/04/16
19:37
Hot Stocks
Karyopharm reports data from Phase 2 SAIL study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:32
12/04/16
12/04
19:32
12/04/16
19:32
Hot Stocks
Acetylon reports preclinical ACY-957 data »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

19:30
12/04/16
12/04
19:30
12/04/16
19:30
Hot Stocks
Global Blood Therapeutics reports Phase 1/2 GBT440 data »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:27
12/04/16
12/04
19:27
12/04/16
19:27
Hot Stocks
Acetylon reports initial Phase 1a/b data for citarinostat in myeloma »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

XLRN

Acceleron

$36.29

1.25 (3.57%)

, CELG

Celgene

$117.63

-1.24 (-1.04%)

19:23
12/04/16
12/04
19:23
12/04/16
19:23
Hot Stocks
Acceleron, Celgene report updated data from Phase 2 luspatercept studies »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$36.29

1.25 (3.57%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

19:05
12/04/16
12/04
19:05
12/04/16
19:05
Hot Stocks
Alnylam reports Phase 2 data on fitusiran in hemophilia »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$122.96

0.95 (0.78%)

19:01
12/04/16
12/04
19:01
12/04/16
19:01
Hot Stocks
Alexion reports data from Phase 1/2 ALXN1210 study »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

LYV

Live Nation

$27.07

-0.44 (-1.60%)

18:58
12/04/16
12/04
18:58
12/04/16
18:58
Hot Stocks
Live Nation acquires 51% stake in Australia's Secret Sounds Group »

Live Nation Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.17

0.42 (0.62%)

18:45
12/04/16
12/04
18:45
12/04/16
18:45
Hot Stocks
Novartis reports Phase 2 data on CTL019 in leukemia »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ABBV

AbbVie

$59.43

0.27 (0.46%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

18:29
12/04/16
12/04
18:29
12/04/16
18:29
Hot Stocks
AbbVie reports five-year IMBRUVICA data, updated RESONATE-2 data »

AbbVie (ABBV) announced…

ABBV

AbbVie

$59.43

0.27 (0.46%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

18:17
12/04/16
12/04
18:17
12/04/16
18:17
Hot Stocks
Celgene, Dana-Farber, U of Arkansas form Myeloma Genome Project »

Celgene, Dana-Farber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

ARQL

ArQule

$1.37

-0.01 (-0.72%)

18:12
12/04/16
12/04
18:12
12/04/16
18:12
Hot Stocks
ArQule reports data presentation on ARQ 092 in sickle cell disease »

ArQule announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$98.50

-0.44 (-0.44%)

, TWX

Time Warner

$93.80

-0.34 (-0.36%)

18:08
12/04/16
12/04
18:08
12/04/16
18:08
Hot Stocks
Box Office Battle: 'Moana,' 'Fantastic Beasts' win post-Thanksgiving weekend »

Disney's (DIS)…

DIS

Disney

$98.50

-0.44 (-0.44%)

TWX

Time Warner

$93.80

-0.34 (-0.36%)

VIA

Viacom

$40.35

-1 (-2.42%)

VIAB

Viacom

$36.52

-0.74 (-1.99%)

SNE

Sony

$28.06

-0.16 (-0.57%)

FOX

21st Century Fox

$27.37

-0.71 (-2.53%)

FOXA

21st Century Fox

$27.40

-0.8 (-2.84%)

LGF

Lionsgate

$22.72

0.02 (0.09%)

CMCSA

Comcast

$68.78

-1.08 (-1.55%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.